Moreover, in a recent study of 96 stage IV NSCLC patients treated with docetaxel plus gemcitabine, we observed that as BRCA1 mRNA levels increased, the probability of response increased and the risk of progression decreased. This evidence concerns the gene BRCA1 and non-small cell lung carcinoma.